Australia's most trusted
source of pharma news
Monday, 07 October 2024
Posted 28 March 2022 AM
In what patients have described as a "true underdog story" Vertex cystic fibrosis (CF) drug Trikafta will be listed on the PBS from 1 April.
The triple combination therapy, dubbed a 'miracle drug' by patients, will be available for CF sufferers aged 12 years and older who have at least one F508del mutation in the CFTR gene.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.